L&G Pharma Breakthrough UCITS ETF (ETR:ETLI)
9.15
+0.09 (1.00%)
Jul 2, 2025, 5:36 PM CET
0.04% (1Y)
Assets | 21.43M |
Expense Ratio | 0.49% |
PE Ratio | n/a |
Dividend (ttm) | n/a |
Dividend Yield | n/a |
Ex-Dividend Date | n/a |
Payout Frequency | n/a |
Payout Ratio | n/a |
1-Year Return | -0.58% |
Volume | 1,846 |
Open | 9.09 |
Previous Close | 9.06 |
Day's Range | 9.09 - 9.18 |
52-Week Low | 8.14 |
52-Week High | 10.66 |
Beta | 0.41 |
Holdings | 40 |
Inception Date | Jan 18, 2018 |
About ETLI
The L&G Pharma Breakthrough UCITS ETF (the Fund) is an exchange traded fund (ETF) that aims to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the Index) subject to the deduction of the ongoing charges and other costs associated with operating the Fund.
Category Sector Equity Biotechnology
Stock Exchange Deutsche Börse Xetra
Ticker Symbol ETLI
Performance
ETLI had a total return of -0.58% in the past year, including dividends. Since the fund's inception, the average annual return has been 1.29%.
Top 10 Holdings
33.42% of assetsName | Symbol | Weight |
---|---|---|
InnoCare Pharma Limited | 9969 | 3.79% |
Pharming Group N.V. | PHARM | 3.71% |
Alnylam Pharmaceuticals, Inc. | ALNY | 3.70% |
BioCryst Pharmaceuticals, Inc. | BCRX | 3.41% |
Ionis Pharmaceuticals, Inc. | IONS | 3.30% |
Kyowa Kirin Co., Ltd. | 4151 | 3.14% |
Zevra Therapeutics, Inc. | ZVRA | 3.12% |
Xeris Biopharma Holdings, Inc. | XERS | 3.11% |
Chugai Pharmaceutical Co., Ltd. | 4519 | 3.09% |
Royalty Pharma plc | RPRX | 3.05% |